Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,518 questions in 135 reviews · Infectious Diseases

current versions

No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Linezolid vs no linezolid Linezolid discontinuationl · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	no estimate extracted	1 study · 65 participants	Ungraded
Linezolid vs no linezolid Treatment failure · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	RR 0.26 [0.1, 0.7]	1 study · 65 participants	Very low
Linezolid vs no linezolid Cure · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	RR 2.36 [1.13, 4.9]	1 study · 65 participants	Very low
Linezolid vs no linezolid Treatment interrupted · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	RR 1.29 [0.31, 5.33]	1 study · 65 participants	Very low
Linezolid vs no linezolid Treatment completed · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	RR 1.45 [0.45, 4.68]	1 study · 65 participants	Very low
Linezolid vs no linezolid Sputum culture conversion at 24 months · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	RR 2.1 [1.3, 3.4]	1 study · 65 participants	Very low
Linezolid vs no linezolid Total adverse eventsg · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	no estimate extracted	1 study · 65 participants	Very low
Linezolid vs no linezolid Serious adverse events · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	no estimate extracted	NR	No studies
Linezolid vs no linezolid Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis Linezolid for drug‐resistant pulmonary tuberculosis (2019) · Cochrane	RR 1.94 [0.18, 20.35]	1 study · 65 participants	Very low
MVA85A vs placebo Active tuberculosis: confirmed by culture or Xpert® MTB/RIF longest reported · HIV‐positive and ‐negative adults and children MVA85A vaccine to enhance BCG for preventing tuberculosis (2019) · Cochrane	RR 0.97 [0.58, 1.62]	2 studies · 3439 participants	Moderate
MVA85A vs placebo Active tuberculosis: started on tuberculosis treatment · HIV‐positive and ‐negative adults and children MVA85A vaccine to enhance BCG for preventing tuberculosis (2019) · Cochrane	RR 1.1 [0.92, 1.33]	3 studies · 3687 participants	Moderate
MVA85A vs placebo Latent tuberculosis · HIV‐positive and ‐negative adults and children MVA85A vaccine to enhance BCG for preventing tuberculosis (2019) · Cochrane	RR 1.01 [0.85, 1.21]	4 studies · 3831 participants	Moderate
MVA85A vs placebo Serious adverse effects · HIV‐positive and ‐negative adults and children MVA85A vaccine to enhance BCG for preventing tuberculosis (2019) · Cochrane	RD 0	3 studies · 3692 participants	High
MVA85A vs placebo Adverse effects of any severity (local reactions of the skin) · HIV‐positive and ‐negative adults and children MVA85A vaccine to enhance BCG for preventing tuberculosis (2019) · Cochrane	no estimate extracted	3 studies · 3187 participants	Moderate
MVA85A vs placebo Adverse effects of any severity (systemic symptoms) · HIV‐positive and ‐negative adults and children MVA85A vaccine to enhance BCG for preventing tuberculosis (2019) · Cochrane	no estimate extracted	1 study · 144 participants	Low
MVA85A vs placebo Adverse events of any severity · HIV‐positive and ‐negative adults and children MVA85A vaccine to enhance BCG for preventing tuberculosis (2019) · Cochrane	RR 1.05 [1.02, 1.08]	4 studies · 3836 participants	High
Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen Relapse · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 3.56 [2.37, 5.37]	3 studies · 2265 participants	Moderate
Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 1.02 [0.58, 1.77]	2 studies · 1993 participants	Moderate
Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen Death from any cause · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 1.06 [0.65, 1.75]	3 studies · 2760 participants	Moderate
Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen Treatment failure · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 0.71 [0.33, 1.52]	3 studies · 2282 participants	Moderate
Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 0.33 [0.08, 1.31]	3 studies · 2282 participants	Low
Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 0.97 [0.74, 1.27]	4 studies · 3548 participants	Moderate
Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens Relapse · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 2.11 [1.56, 2.84]	2 studies · 1633 participants	Moderate
Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens Death from any cause · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 0.9 [0.53, 1.53]	2 studies · 1886 participants	Moderate
Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens Treatment failure · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 0.93 [0.51, 1.7]	2 studies · 1657 participants	Moderate
Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis (2019) · Cochrane	RR 0.24 [0.01, 5.01]	1 study · 301 participants	Very low
Rapid antiretroviral therapy (ART) vs standard care Mortality at 12 months · people living with HIV Rapid initiation of antiretroviral therapy for people living with HIV (2019) · Cochrane	RR 0.72 [0.51, 1.01]	7 studies · 5451 participants	Very low
Rapid antiretroviral therapy (ART) vs standard care Virological suppression at 12 months · people living with HIV Rapid initiation of antiretroviral therapy for people living with HIV (2019) · Cochrane	RR 1.18 [1.1, 1.27]	4 studies · 2719 participants	Moderate
Rapid antiretroviral therapy (ART) vs standard care Retention in care at 12 months · people living with HIV Rapid initiation of antiretroviral therapy for people living with HIV (2019) · Cochrane	RR 1.22 [1.11, 1.35]	6 studies · 5001 participants	Low
Rapid antiretroviral therapy (ART) vs standard care Uptake of ART at 90 days · people living with HIV Rapid initiation of antiretroviral therapy for people living with HIV (2019) · Cochrane	RR 1.31 [1.18, 1.45]	4 studies · 11404 participants	Low
Rapid antiretroviral therapy (ART) vs standard care Uptake of ART at 12 months · people living with HIV Rapid initiation of antiretroviral therapy for people living with HIV (2019) · Cochrane	RR 1.09 [1.06, 1.12]	4 studies · 3713 participants	Moderate
Rapid antiretroviral therapy (ART) vs standard care Treatment modification · people living with HIV Rapid initiation of antiretroviral therapy for people living with HIV (2019) · Cochrane	RR 7.89 [0.76, 81.74]	2 studies · 977 participants	Very low
Insecticide‐treated bed nets and curtains vs no nets Child mortality from all causes · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Rate ratio 0.83 [0.77, 0.89]	5 studies · 200833 participants	High
Insecticide‐treated bed nets and curtains vs untreated nets Plasmodium falciparum uncomplicated episodes · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Rate ratio 0.58 [0.44, 0.78]	5 studies · 2036 participants	High
Insecticide‐treated bed nets and curtains vs untreated nets Plasmodium vivax uncomplicated episodes l · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Rate ratio 0.73 [0.51, 1.05]	3 studies · 1535 participants	Low
Insecticide‐treated bed nets and curtains vs untreated nets Any Plasmodium spp. uncomplicated episodes (cumulative incidence) · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Risk ratio 0.47 [0.17, 1.28]	2 studies · 8082 participants	Moderate
Insecticide‐treated bed nets and curtains vs untreated nets P falciparum prevalence · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Risk ratio 0.91 [0.78, 1.05]	3 studies · 2259 participants	Moderate
Insecticide‐treated bed nets and curtains vs untreated nets P vivax prevalence · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Risk ratio 0.68 [0.25, 1.85]	1 study · 350 participants	Very low
Insecticide‐treated bed nets and curtains vs untreated nets Any Plasmodium spp. prevalence · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Risk ratio 0.17 [0.05, 0.53]	1 study · 924 participants	Very low
Insecticide‐treated bed nets and curtains vs untreated nets Anaemia (mean packed cell volume) · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Mean difference 0.48	2 studies · 1909 participants	Low
Insecticide‐treated bed nets and curtains vs no nets Plasmodium falciparum uncomplicated episodesg · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Rate ratio 0.55 [0.48, 0.64]	5 studies · 35551 participants	High
Insecticide‐treated bed nets and curtains vs no nets Plasmodium vivax uncomplicated episodes (cumulative incidence) · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Risk ratio 0.61 [0.48, 0.77]	2 studies · 10967 participants	Moderate
Insecticide‐treated bed nets and curtains vs no nets Any Plasmodium spp. uncomplicated episodes · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Rate ratio 0.5 [0.28, 0.9]	1 study · 8395 participants	Low
Insecticide‐treated bed nets and curtains vs no nets P falciparum prevalence · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Risk ratio 0.83 [0.71, 0.98]	6 studies · 18809 participants	High
Insecticide‐treated bed nets and curtains vs no nets P vivax prevalence · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Risk ratio 1 [0.75, 1.34]	2 studies · 10967 participants	Low
Insecticide‐treated bed nets and curtains vs no nets Severe malaria episodes · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Rate ratio 0.56 [0.38, 0.82]	2 studies · 31173 participants	High
Insecticide‐treated bed nets and curtains vs no nets Anaemia (mean packed cell volume) · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Mean difference 1.29 [0.42, 2.16]	5 studies · 11489 participants	High
Insecticide‐treated bed nets and curtains vs untreated nets Child mortality from all causes · people of all ages living in malaria transmission settings Insecticide‐treated nets for preventing malaria (2018) · Cochrane	Rate ratio 0.67 [0.36, 1.23]	2 studies · 25389 participants	Moderate
Ty21a vaccine (three doses) vs control Cases of typhoid fever, Year 1 · adults and children aged 5 years of age and older Vaccines for preventing typhoid fever (2018) · Cochrane	RR 0.55 [0.35, 0.86]	3 studies · 76296 participants	Moderate
Vi polysaccharide vaccine (1 dose) vs control Fever · adults and children of 2 years of age and older Vaccines for preventing typhoid fever (2018) · Cochrane	RR 0.98 [0.84, 1.13]	3 studies · 132261 participants	Moderate